Literature DB >> 8929992

Expression of glial cell line-derived growth factor mRNA in the spinal cord and muscle in amyotrophic lateral sclerosis.

M Yamamoto1, G Sobue, K Yamamoto, S Terao, T Mitsuma.   

Abstract

The steady-state expression levels of glial cell line-derived growth factor (GDNF) mRNA was studied in the post mortem spinal cord and muscle of patients with amyotrophic lateral sclerosis (ALS), by reverse transcription followed by polymerase chain reaction (RT-PCR). GDNF mRNA levels in the lumbar cord were significantly increased in ALS as compared with controls. On the other hand, GDNF mRNA levels were significantly lower in the muscle in ALS patients. The increase of GDNF mRNA in the spinal cord mostly reflected an increase in the anterior horn, anterior and lateral columns, where the pathological involvement was severe. In the posterior column and posterior horn with less pathological involvement, the increase was less. These results suggest that GDNF mRNA levels are inversely regulated between the spinal cord and muscle in ALS, increased in the spinal cord and lowered in the muscle, in correlation with the pathological severity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8929992     DOI: 10.1016/0304-3940(96)12342-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

1.  Expression of GDNF and GDNFR-alpha mRNAs in muscles of patients with motor neuron diseases.

Authors:  M Yamamoto; N Mitsuma; A Inukai; Y Ito; M Li; T Mitsuma; G Sobue
Journal:  Neurochem Res       Date:  1999-06       Impact factor: 3.996

Review 2.  Molecular mechanisms regulating motor neuron development and degeneration.

Authors:  T J Kilpatrick; M Soilu-Hänninen
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

3.  Expression of mRNAs for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and their receptors (CNTFR alpha, LIFR beta, IL-6R alpha, and gp130) in human peripheral neuropathies.

Authors:  Y Ito; M Yamamoto; N Mitsuma; M Li; N Hattori; G Sobue
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

4.  Expression of mRNAs for neurotrophic factors (NGF, BDNF, NT-3, and GDNF) and their receptors (p75NGFR, trkA, trkB, and trkC) in the adult human peripheral nervous system and nonneural tissues.

Authors:  M Yamamoto; G Sobue; K Yamamoto; S Terao; T Mitsuma
Journal:  Neurochem Res       Date:  1996-08       Impact factor: 3.996

5.  Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis.

Authors:  T Mutoh; G Sobue; T Hamano; M Kuriyama; M Hirayama; M Yamamoto; T Mitsuma
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

6.  Glial cell line-derived neurotrophic factor protein content in rat skeletal muscle is altered by increased physical activity in vivo and in vitro.

Authors:  M J McCullough; N G Peplinski; K R Kinnell; J M Spitsbergen
Journal:  Neuroscience       Date:  2010-11-23       Impact factor: 3.590

Review 7.  Neuromuscular Junction Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Sagar Verma; Shiffali Khurana; Abhishek Vats; Bandana Sahu; Nirmal Kumar Ganguly; Pradip Chakraborti; Mandaville Gourie-Devi; Vibha Taneja
Journal:  Mol Neurobiol       Date:  2022-01-08       Impact factor: 5.590

8.  Short-term exercise increases GDNF protein levels in the spinal cord of young and old rats.

Authors:  M J McCullough; A M Gyorkos; J M Spitsbergen
Journal:  Neuroscience       Date:  2013-03-14       Impact factor: 3.590

9.  Differential expression of c-Ret in motor neurons versus non-neuronal cells is linked to the pathogenesis of ALS.

Authors:  Hoon Ryu; Gye Sun Jeon; Neil R Cashman; Neil W Kowall; Junghee Lee
Journal:  Lab Invest       Date:  2011-01-31       Impact factor: 5.662

10.  Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis.

Authors:  Dan Krakora; Corey Macrander; Masatoshi Suzuki
Journal:  Neurol Res Int       Date:  2012-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.